KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Gross Margin (2018 - 2025)

Ionis Pharmaceuticals (IONS) has 8 years of Gross Margin data on record, last reported at 98.51% in Q3 2025.

  • For Q3 2025, Gross Margin fell 69.0% year-over-year to 98.51%; the TTM value through Sep 2025 reached 98.51%, up 32.0%, while the annual FY2024 figure was 98.41%, 43.0% down from the prior year.
  • Gross Margin reached 98.51% in Q3 2025 per IONS's latest filing, roughly flat from 98.51% in the prior quarter.
  • Across five years, Gross Margin topped out at 99.2% in Q3 2024 and bottomed at 13780.0% in Q2 2024.
  • Average Gross Margin over 5 years is 636.23%, with a median of 98.31% recorded in 2024.
  • Peak YoY movement for Gross Margin: crashed -1387865bps in 2024, then surged 1387851bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 96.29% in 2021, then rose by 1bps to 97.57% in 2022, then rose by 2bps to 99.06% in 2023, then decreased by -1bps to 98.31% in 2024, then grew by 0bps to 98.51% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 98.51% in Q3 2025, 98.51% in Q2 2025, and 98.89% in Q1 2025.